UA113623C2 - Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) - Google Patents
Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)Info
- Publication number
- UA113623C2 UA113623C2 UAA201312686A UAA201312686A UA113623C2 UA 113623 C2 UA113623 C2 UA 113623C2 UA A201312686 A UAA201312686 A UA A201312686A UA A201312686 A UAA201312686 A UA A201312686A UA 113623 C2 UA113623 C2 UA 113623C2
- Authority
- UA
- Ukraine
- Prior art keywords
- factor
- tissue factor
- tfpi
- monoclonal antibody
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Винахід належить до ізольованого моноклонального антитіла, яке зв'язується зі специфічними епітопами інгібітору шляху тканинного фактора людини (TFPI), ізольованої молекули нуклеїнової кислоти, що кодують їх, фармацевтичної композиції, яка включає анти-TFPI моноклональне антитіло і способу лікування дефіцитів або вад коагуляції шляхом введення такого антитіла.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471101P | 2011-04-01 | 2011-04-01 | |
| PCT/US2012/031538 WO2012135671A2 (en) | 2011-04-01 | 2012-03-30 | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA113623C2 true UA113623C2 (uk) | 2017-02-27 |
Family
ID=46932389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201312686A UA113623C2 (uk) | 2011-04-01 | 2012-03-30 | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) |
Country Status (37)
| Country | Link |
|---|---|
| US (5) | US20140294832A1 (uk) |
| EP (1) | EP2694544B1 (uk) |
| JP (4) | JP6170903B2 (uk) |
| KR (2) | KR20190079698A (uk) |
| CN (2) | CN103797030B (uk) |
| AU (3) | AU2012236296A1 (uk) |
| BR (1) | BR112013025376A2 (uk) |
| CA (2) | CA2831907C (uk) |
| CL (1) | CL2013002811A1 (uk) |
| CO (1) | CO6890074A2 (uk) |
| CR (1) | CR20130499A (uk) |
| CU (1) | CU20130128A7 (uk) |
| CY (1) | CY1121538T1 (uk) |
| DK (1) | DK2694544T3 (uk) |
| DO (1) | DOP2013000218A (uk) |
| EA (2) | EA034214B1 (uk) |
| EC (1) | ECSP13012913A (uk) |
| ES (1) | ES2722824T3 (uk) |
| GT (1) | GT201300229A (uk) |
| HK (1) | HK1243426A1 (uk) |
| HR (1) | HRP20190467T1 (uk) |
| HU (1) | HUE042706T2 (uk) |
| IL (4) | IL228633B (uk) |
| LT (1) | LT2694544T (uk) |
| MX (1) | MX2013011218A (uk) |
| MY (2) | MY165499A (uk) |
| PE (1) | PE20141149A1 (uk) |
| PH (4) | PH12013502039A1 (uk) |
| PL (1) | PL2694544T3 (uk) |
| PT (1) | PT2694544T (uk) |
| RS (1) | RS58633B1 (uk) |
| SG (2) | SG10201602606UA (uk) |
| SI (1) | SI2694544T1 (uk) |
| TR (1) | TR201905101T4 (uk) |
| UA (1) | UA113623C2 (uk) |
| WO (1) | WO2012135671A2 (uk) |
| ZA (1) | ZA201308169B (uk) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101792032B1 (ko) | 2008-12-19 | 2017-11-02 | 백스터 인터내셔널 인코포레이티드 | Ｔｆｐｉ 억제제 및 사용 방법 |
| KR101745394B1 (ko) | 2008-12-22 | 2017-06-09 | 노보 노르디스크 에이/에스 | 조직 인자 경로 억제자에 대한 항체 |
| SI2542257T1 (en) | 2010-03-01 | 2018-01-31 | Bayer Healthcare Llc | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) |
| ES2983470T3 (es) | 2010-03-19 | 2024-10-23 | Takeda Pharmaceuticals Co | Inhibidores del TFPI y métodos de uso |
| DK2694544T3 (en) * | 2011-04-01 | 2019-04-15 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES AGAINST TIBI FACTOR ACTIVITY INHIBITOR (TFPI) |
| CN109134614A (zh) * | 2012-03-21 | 2019-01-04 | 百深有限责任公司 | Tfpi抑制剂及其使用方法 |
| CA2868789A1 (en) * | 2012-03-30 | 2013-10-03 | Bayer Healthcare Llc | Protease-regulated antibodies |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| PT2970497T (pt) | 2013-03-15 | 2018-01-30 | Bayer Healthcare Llc | Variantes de anticorpo anti-tfpi com ligação diferencial ao longo de intervalo de ph para melhoria das propriedades farmacocinéticas |
| WO2014140240A1 (en) | 2013-03-15 | 2014-09-18 | Novo Nordisk A/S | Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor |
| WO2015007880A1 (en) * | 2013-07-19 | 2015-01-22 | Novo Nordisk A/S | Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
| US11279771B2 (en) * | 2014-09-17 | 2022-03-22 | Novo Nordisk A/S | Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161) |
| US10266607B2 (en) * | 2015-02-25 | 2019-04-23 | Mogam Institute For Biomedical Research | Antibody binding to TFPI and composition comprising the same |
| EP3337827A2 (en) * | 2015-08-19 | 2018-06-27 | Pfizer Inc | Tissue factor pathway inhibitor antibodies and uses thereof |
| WO2020021890A1 (ja) * | 2018-07-25 | 2020-01-30 | ソニー株式会社 | 血液凝固系解析装置 |
| CN112442127A (zh) * | 2019-08-29 | 2021-03-05 | 苏州康宁杰瑞生物科技有限公司 | 针对tfpi的单克隆抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06153985A (ja) * | 1992-11-16 | 1994-06-03 | Teijin Ltd | モノクローナル抗体 |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| KR101745394B1 (ko) * | 2008-12-22 | 2017-06-09 | 노보 노르디스크 에이/에스 | 조직 인자 경로 억제자에 대한 항체 |
| SI2542257T1 (en) * | 2010-03-01 | 2018-01-31 | Bayer Healthcare Llc | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) |
| DK2694544T3 (en) * | 2011-04-01 | 2019-04-15 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES AGAINST TIBI FACTOR ACTIVITY INHIBITOR (TFPI) |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
-
2012
- 2012-03-30 DK DK12762959.0T patent/DK2694544T3/en active
- 2012-03-30 BR BR112013025376A patent/BR112013025376A2/pt active Search and Examination
- 2012-03-30 EP EP12762959.0A patent/EP2694544B1/en active Active
- 2012-03-30 WO PCT/US2012/031538 patent/WO2012135671A2/en active Application Filing
- 2012-03-30 SG SG10201602606UA patent/SG10201602606UA/en unknown
- 2012-03-30 KR KR1020197018445A patent/KR20190079698A/ko not_active Application Discontinuation
- 2012-03-30 UA UAA201312686A patent/UA113623C2/uk unknown
- 2012-03-30 TR TR2019/05101T patent/TR201905101T4/tr unknown
- 2012-03-30 AU AU2012236296A patent/AU2012236296A1/en not_active Abandoned
- 2012-03-30 MY MYPI2013701814A patent/MY165499A/en unknown
- 2012-03-30 JP JP2014502846A patent/JP6170903B2/ja not_active Expired - Fee Related
- 2012-03-30 HU HUE12762959A patent/HUE042706T2/hu unknown
- 2012-03-30 EA EA201301107A patent/EA034214B1/ru not_active IP Right Cessation
- 2012-03-30 MX MX2013011218A patent/MX2013011218A/es unknown
- 2012-03-30 RS RS20190338A patent/RS58633B1/sr unknown
- 2012-03-30 MY MYPI2017001205A patent/MY190951A/en unknown
- 2012-03-30 SI SI201231558T patent/SI2694544T1/sl unknown
- 2012-03-30 LT LTEP12762959.0T patent/LT2694544T/lt unknown
- 2012-03-30 CN CN201280026938.XA patent/CN103797030B/zh not_active Expired - Fee Related
- 2012-03-30 PL PL12762959T patent/PL2694544T3/pl unknown
- 2012-03-30 EA EA201991704A patent/EA201991704A3/ru unknown
- 2012-03-30 SG SG2013071477A patent/SG193594A1/en unknown
- 2012-03-30 ES ES12762959T patent/ES2722824T3/es active Active
- 2012-03-30 PE PE2013002137A patent/PE20141149A1/es active IP Right Grant
- 2012-03-30 CA CA2831907A patent/CA2831907C/en not_active Expired - Fee Related
- 2012-03-30 US US14/009,334 patent/US20140294832A1/en not_active Abandoned
- 2012-03-30 CA CA3068997A patent/CA3068997A1/en not_active Abandoned
- 2012-03-30 CN CN201710275470.2A patent/CN107090046A/zh active Pending
- 2012-03-30 KR KR1020137028821A patent/KR101995302B1/ko active IP Right Grant
- 2012-03-30 PT PT12762959T patent/PT2694544T/pt unknown
-
2013
- 2013-09-27 GT GT201300229A patent/GT201300229A/es unknown
- 2013-09-30 CU CU2013000128A patent/CU20130128A7/es unknown
- 2013-09-30 CL CL2013002811A patent/CL2013002811A1/es unknown
- 2013-09-30 PH PH12013502039A patent/PH12013502039A1/en unknown
- 2013-09-30 DO DO2013000218A patent/DOP2013000218A/es unknown
- 2013-09-30 CR CR20130499A patent/CR20130499A/es unknown
- 2013-09-30 IL IL228633A patent/IL228633B/en active IP Right Grant
- 2013-10-01 EC ECSP13012913 patent/ECSP13012913A/es unknown
- 2013-10-01 CO CO13233113A patent/CO6890074A2/es unknown
- 2013-10-31 ZA ZA2013/08169A patent/ZA201308169B/en unknown
-
2016
- 2016-07-27 US US15/221,104 patent/US20170107298A1/en not_active Abandoned
-
2017
- 2017-02-17 JP JP2017027825A patent/JP6363747B2/ja not_active Expired - Fee Related
- 2017-05-10 AU AU2017203105A patent/AU2017203105A1/en not_active Abandoned
-
2018
- 2018-01-22 US US15/877,349 patent/US20180194857A1/en not_active Abandoned
- 2018-01-25 IL IL257145A patent/IL257145A/en unknown
- 2018-02-22 HK HK18102557.1A patent/HK1243426A1/zh unknown
- 2018-06-28 JP JP2018122610A patent/JP2018172411A/ja active Pending
- 2018-12-27 US US16/234,239 patent/US20190194353A1/en not_active Abandoned
-
2019
- 2019-02-28 PH PH12019500441A patent/PH12019500441A1/en unknown
- 2019-02-28 PH PH12019500439A patent/PH12019500439A1/en unknown
- 2019-02-28 PH PH12019500440A patent/PH12019500440A1/en unknown
- 2019-03-08 HR HRP20190467TT patent/HRP20190467T1/hr unknown
- 2019-03-15 AU AU2019201814A patent/AU2019201814A1/en not_active Abandoned
- 2019-03-22 CY CY20191100343T patent/CY1121538T1/el unknown
-
2020
- 2020-05-14 IL IL274686A patent/IL274686B/en unknown
- 2020-10-20 JP JP2020176145A patent/JP2021019619A/ja not_active Withdrawn
-
2021
- 2021-03-24 US US17/211,631 patent/US20220041752A1/en not_active Abandoned
- 2021-06-09 IL IL283829A patent/IL283829A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| CY1120398T1 (el) | Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη | |
| UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
| CY1119445T1 (el) | Αντισωματα εναντι του ανθρωπινου gdf8 | |
| UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
| JOP20160131B1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| UA114891C2 (uk) | ІЗОЛЬОВАНЕ АНТИТІЛО ЛЮДИНИ, ЯКЕ СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З АНГІОПОЕТИНПОДІБНИМ БІЛКОМ 3 ЛЮДИНИ (hАNGPTL3), ТА ЙОГО ЗАСТОСУВАННЯ | |
| EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| UA109658C2 (xx) | Антитіло проти cgrp | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| UA100377C2 (uk) | Антитіло, яке специфічно зв'язується з інтерлейкіном 25 (il-25) | |
| MY184189A (en) | Methods of treating nail and scalp psoriasis | |
| PE20141683A1 (es) | Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs) | |
| MX2015002465A (es) | Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1). | |
| UA109148C2 (uk) | Композиції на основі антитіла проти vegfr-3 | |
| UA108207C2 (xx) | Високоафінне людське антитіло до людського ангіопоетину-2 | |
| TN2013000068A1 (en) | Anti-vegfr-3 antibody compositions | |
| TH149802A (th) | โปรตีนจับเกาะแอนติเจน | |
| TH135279A (th) | องค์ประกอบแอนติ-vegfr-3 แอนติบอดี |